From e680ba3f097962a32b8bdc604b1e5da96b009add Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 14 Apr 2026 16:52:39 +0000 Subject: [PATCH] auto-fix: strip 1 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- .../2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md b/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md index 59b3d1443..8c7ae80f6 100644 --- a/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md +++ b/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md @@ -41,6 +41,6 @@ Published in *Circulation: Cardiovascular Quality and Outcomes*, 2024. Large US **Context:** Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods. ## Curator Notes -PRIMARY CONNECTION: [[Session 13 claim candidate: access-mediated pharmacological ceiling]]; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss +PRIMARY CONNECTION: Session 13 claim candidate: access-mediated pharmacological ceiling; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly.